Journals / Nöropsikiyatri Arşivi / 2021 / Cilt: 58 - Sayı: 2

Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis

Yüksek Dereceli Gliomalarda Azalmış Serum sRANKL ve sTREM2 Seviyeleri: Prognoz ile İlişkisi

Pages
133–136
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall survival duration of the patients was recorded.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: High-grade gliomas (HGG), including Glioblastoma multiforme (GBM), account for the majority of primary brain tumors.
📊
Key Findings & Data:The objective of this study was to investigate the prognostic value of sRANKL and sTREM2 levels in HGG patients.
💡
Conclusion & Impact:Overall survival duration of the patients was recorded.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: High-grade gliomas (HGG), including Glioblastoma multiforme (GBM), account for the majority of primary brain tumors. Nevertheless, prognostic and diagnostic biomarkers are quite limited for HGG. The objective of this study was to investigate the prognostic value of sRANKL and sTREM2 levels in HGG patients. Methods: Twelve consecutive patients with HGG, 14 patients with nonglial tumors (non-GT) and 20 age and gender-matched healthy controls were recruited. Overall survival duration of the patients was recorded. Pre-operative serum levels of sRANKL and sTREM2 were measured by ELISA. Tumors of HGG patients were analyzed by immunohistochemical staining for p53 and Ki67 and percentage scores were calculated. Results: Patients with HGG and non-GT showed lower serum sRANKL and sTREM2 levels than healthy individuals. Levels of sRANKL were inversely correlated with the overall survival of patients (p=0.002, R=0.787), while sTREM2 levels were inversely correlated with p53 score (p=0.018, R=-0.666) but not survival. Conclusion: Brain tumor patients show suppressed levels of glial activity biomarkers in the peripheral circulation. Serum sRANKL levels may serve as a potential prognostic biomarker for HGG.

Özet

Amaç: Glioblastoma multiforme (GBM) dâhil olmak üzere yüksekdereceli gliomalar (YDG), birincil beyin tümörlerinin çoğunluğunuoluşturur. Bununla birlikte, tanısal ve prognostik biyobelirteçler YDGiçin oldukça sınırlıdır. Bu çalışmanın amacı, YDG hastalarında sRANKL vesTREM2 düzeylerinin prognostik değerini araştırmaktır.Yöntem: Çalışmaya 12 YDG hastası, 14 tümörü glial (GT) kaynaklıolmayan hasta ile 20 yaş ve cinsiyet uyumlu sağlıklı kontrol dâhil edildi.Hastaların genel sağkalım süreleri kaydedildi. sRANKL ve sTREM2’ninoperasyon öncesi serum seviyeleri ELISA yöntemi ile ölçüldü. YDGhastalarının tümörleri p53 ve Ki67 için immünohistokimyasal boyama ileanaliz edilerek yüzde skorları hesaplandı.Bulgular: YDG’si olan ve GT olmayan hastalar, sağlıklı bireylere göre dahadüşük serum sRANKL ve sTREM2 seviyeleri gösterdi. sRANKL seviyelerihastaların genel sağkalımı ile ters orantılıyken (p=0,002, R=-0,787),sTREM2 seviyelerinin ise p53 skoru ile ters orantılı olduğu saptandı(p=0,018, R=-0,666).Sonuç: Beyin tümörü bulunan hastalarda, periferik dolaşımdaki glialaktivite biyobelirteçlerinin seviyeleri gösterilmiştir. Serum sRANKLseviyeleri, YDG hastaları için potansiyel bir prognostik biyobelirteçolabilir.

🔖

Cite This Article

EFENDİOĞLU, M., ŞANLI, E., TÜRKOĞLU, C., BALAK, N. (2021). Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis. Nöropsikiyatri Arşivi, Cilt: 58 - Sayı: 2, 133–136. https://ajindex.com/articles/340776

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Balak N, Türkoğlu R, Sarı R, Aslan B, Zemheri E, Işık N. Favored gyral sites of supratentorial astrocytic tumors. Neurol Asia 2011
  2. 71–79. http://www. neurology-asia.org/articles/neuroasia-2011-16(1)-071.pdf 2. Martínez-Garcia M, Álvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X, Martínez-Aguillo M, Navarro LM, Vaz-Salgado MA, Gil-Gil M. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol 2018
  3. 22–28. [CrossRef] 3. Davis ME. Glioblastoma: Overview of disease and treatment. Clin J Oncol Nurs 2016
  4. S1–S8. [CrossRef] 4. Ryken TC, Aygun N, Morris J, Schweizer M, Nair R, Spracklen C, Kalkanis SN, Olson JJ. The role of imaging in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2014
  5. 435–460. [CrossRef] 5. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007
  6. 9 Suppl 1:S1. [CrossRef] 6. Raaz-Schrauder D, Schrauder MG, Stumpf C, Lewczuk P, Kilian T, Dietel B, Garlichs CD, Schlundt C, Achenbach S, Klinghammer L. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk. Heart Vessels 2017
  7. 1304–1313. [CrossRef] 7. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002
  8. 549–553. [CrossRef] 8. Rao S, Cronin SJF, Sigl V, Penninger JM. RANKL and RANK. From Mammalian Physiology to Cancer Treatment. Trends Cell Biol 2018
  9. 213–223. [CrossRef] 9. Naumnik W, Płońska I, Ossolińska M, Nikliński J, Naumnik B. Prognostic value of osteoprotegerin and sRANKL in bronchoalveolar lavage fluid of patients with advanced non-small cell lung cancer. Adv Exp Med Biol 2018
  10. 1–6. [CrossRef] 10. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006
  11. 1372–1379. [CrossRef] 11. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010
  12. 98–102. [CrossRef] 12. Bekris LM, Khrestian M, Dyne E, Shao Y, Pillai JA, Rao SM, Bemiller SM, Lamb B, Fernandez HH, Leverenz